Nuclear Translocation of RELB Is Increased in Diseased Human Liver and Promotes Ductular Reaction and Biliary Fibrosis in Mice.

BACKGROUND & AIMS Cholangiocyte proliferation and ductular reaction contribute to the onset and progression of liver diseases. Little is known about the role of the transcription factor nuclear factor-κB (NF-κB) in this process. We investigated the activities of the RELB proto-oncogene NF-κB subunit in human cholangiocytes and in mouse models of liver disease characterized by a ductular reaction. METHODS We obtained liver tissue samples from patients with primary sclerosing cholangitis, primary biliary cholangitis, hepatitis B or C virus infection, autoimmune hepatitis, alcoholic liver disease, or without these diseases (controls) from a tissue bank in Germany. Tissues were analyzed by immunohistochemistry for levels of RELB and lymphotoxin β (LTB). We studied mice with liver parenchymal cell (LPC)-specific disruption of the cylindromatosis (CYLD) lysine 63 deubiquitinase gene (Cyld), with or without disruption of Relb (CyldΔLPC mice and Cyld/RelbΔLPC mice) and compared them with C57BL/6 mice (controls). Mice were fed 5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) or standard chow diets to induce biliary injury or were given injections of CCl4 to induce non-cholestatic liver fibrosis. Liver tissues were analyzed by histology, immunohistochemistry, immunoblots, in situ hybridization, and quantitative real-time polymerase chain reaction. Cholangiocytes were isolated from normal human liver, incubated with LTB receptor agonist, and transfected with small interfering RNAs to knock down RELB. RESULTS In liver tissues from patients with primary sclerosing cholangitis, primary biliary cholangitis, chronic infection with hepatitis B or C virus, autoimmune hepatitis, or alcoholic liver disease, we detected increased nuclear translocation of RELB and increased levels of LTB in cholangiocytes that formed reactive bile ducts compared with control liver tissues. Human cholangiocytes, but not those with RELB knockdown, proliferated with exposure to LTB. The phenotype of CyldΔLPC mice, which included ductular reaction, oval cell activation, and biliary fibrosis, was completely lost from Cyld/RelbΔLPC mice. Compared with livers from control mice, livers from CyldΔLPC mice (but not Cyld/RelbΔLPC mice) had increased levels of mRNAs encoding cytokines (LTB; CD40; and tumor necrosis factor superfamily [TNFSF] members TNFSF11 [RANKL], TNFSF13B [BAFF], and TNFSF14 [LIGHT]) produced by reactive cholangiocytes. However, these strains of mice developed similar levels of liver fibrosis in response to CCl4 exposure. CyldΔLPC mice and Cyld/RelbΔLPC mice had improved liver function on the DDC diet compared with control mice fed the DDC diet. CONCLUSION Reactive bile ducts in patients with chronic liver diseases have increased levels of LTB and nuclear translocation of RELB. RELB is required for the ductular reaction and development of biliary fibrosis in CyldΔLPC mice. Deletion of RELB and CYLD from LPCs protects mice from DDC-induced cholestatic liver fibrosis.

[1]  T. Karlsen,et al.  Hepatic Stem/Progenitor Cell Activation Differs between Primary Sclerosing and Primary Biliary Cholangitis. , 2017, The American journal of pathology.

[2]  S. Glaser,et al.  Mechanisms of cholangiocyte responses to injury. , 2017, Biochimica et biophysica acta. Molecular basis of disease.

[3]  Darjus F. Tschaharganeh,et al.  Kupffer Cell-Derived Tnf Triggers Cholangiocellular Tumorigenesis through JNK due to Chronic Mitochondrial Dysfunction and ROS. , 2017, Cancer cell.

[4]  S. V. D. van de Graaf,et al.  Bile Acid Uptake Transporters as Targets for Therapy , 2017, Digestive Diseases.

[5]  T. Luedde,et al.  IκB kinaseα/β control biliary homeostasis and hepatocarcinogenesis in mice by phosphorylating the cell‐death mediator receptor‐interacting protein kinase 1 , 2016, Hepatology.

[6]  C. Ware,et al.  The NF-κB subunit RelB controls p100 processing by competing with the kinases NIK and IKK1 for binding to p100 , 2016, Science Signaling.

[7]  M. Roncalli,et al.  Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis , 2016, PloS one.

[8]  Vinay Tergaonkar,et al.  Noncanonical NF-κB Signaling in Health and Disease. , 2016, Trends in molecular medicine.

[9]  F. Bassermann,et al.  BCL3 Reduces the Sterile Inflammatory Response in Pancreatic and Biliary Tissues. , 2016, Gastroenterology.

[10]  C. Levy,et al.  Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis , 2015, Clinical and Translational Gastroenterology.

[11]  T. Matsui,et al.  Disease susceptibility genes shared by primary biliary cirrhosis and Crohn’s disease in the Japanese population , 2015, Journal of Human Genetics.

[12]  G. Alpini,et al.  CCN1 induces hepatic ductular reaction through integrin αvβ₅-mediated activation of NF-κB. , 2015, The Journal of clinical investigation.

[13]  P. Kang,et al.  A new Mdr2(-/-) mouse model of sclerosing cholangitis with rapid fibrosis progression, early-onset portal hypertension, and liver cancer. , 2015, The American journal of pathology.

[14]  J. L. Bermejo,et al.  Nuclear Expression of the Deubiquitinase CYLD Is Associated with Improved Survival in Human Hepatocellular Carcinoma , 2014, PloS one.

[15]  D. Jäger,et al.  Beyond Cell Death – Antiapoptotic Bcl-2 Proteins Regulate Migration and Invasion of Colorectal Cancer Cells In Vitro , 2013, PloS one.

[16]  D. Jäger,et al.  Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice. , 2012, Journal of hepatology.

[17]  N. LaRusso,et al.  Up‐regulation of microRNA 506 leads to decreased Cl−/HCO3− anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis , 2012, Hepatology.

[18]  G. Kollias,et al.  Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer. , 2012, Cancer cell.

[19]  Shao-Cong Sun.  The noncanonical NF‐κB pathway , 2012, Immunological reviews.

[20]  C. Beaumont,et al.  Protoporphyrin retention in hepatocytes and Kupffer cells prevents sclerosing cholangitis in erythropoietic protoporphyria mouse model. , 2011, Gastroenterology.

[21]  T. Luedde,et al.  NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma , 2011, Nature Reviews Gastroenterology &Hepatology.

[22]  Thomas J. Fuchs,et al.  TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. , 2010, Cancer cell.

[23]  M. Ebrahimkhani,et al.  The c‐Rel subunit of nuclear factor‐κB regulates murine liver inflammation, wound‐healing, and hepatocyte proliferation , 2010, Hepatology.

[24]  S-C Sun.  CYLD: a tumor suppressor deubiquitinase regulating NF-κB activation and diverse biological processes , 2010, Cell Death and Differentiation.

[25]  M. Kurrer,et al.  A lymphotoxin-driven pathway to hepatocellular carcinoma. , 2009, Cancer cell.

[26]  M. Karin,et al.  Regulation and function of NF-kappaB transcription factors in the immune system. , 2009, Annual review of immunology.

[27]  J. Olynyk,et al.  Lymphotoxin‐β receptor signaling regulates hepatic stellate cell function and wound healing in a murine model of chronic liver injury , 2009, Hepatology.

[28]  S. Ghosh,et al.  Shared Principles in NF-κB Signaling , 2008, Cell.

[29]  P. Galle,et al.  Regulation of B cell homeostasis and activation by the tumor suppressor gene CYLD , 2007, The Journal of experimental medicine.

[30]  K. Zatloukal,et al.  A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. , 2007, The American journal of pathology.

[31]  G. Gores,et al.  Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. , 2006, The Journal of clinical investigation.

[32]  K. Zatloukal,et al.  Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. , 2006, The American journal of pathology.

[33]  I. Leclercq,et al.  NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. , 2005, Gastroenterology.

[34]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[35]  D. Keppler,et al.  Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis , 2005, Hepatology.

[36]  J. Iredale,et al.  Modeling liver fibrosis in rodents. , 2005, Methods in molecular medicine.

[37]  N. LaRusso,et al.  The cholangiopathies: disorders of biliary epithelia. , 2004, Gastroenterology.

[38]  H. Cortez‐Pinto,et al.  Hepatocyte Apoptosis, Expression of Death Receptors, and Activation of NF-κB in the Liver of Nonalcoholic and Alcoholic Steatohepatitis Patients , 2004, The American Journal of Gastroenterology.

[39]  D. Green,et al.  RelB/p50 Dimers Are Differentially Regulated by Tumor Necrosis Factor-α and Lymphotoxin-β Receptor Activation , 2003, Journal of Biological Chemistry.

[40]  D. Green,et al.  RelB/p50 dimers are differentially regulated by TNF-α and lymphotoxin-β receptor activation: critical roles for p100 , 2003 .

[41]  Jürgen R. Müller,et al.  Lymphotoxin β Receptor Induces Sequential Activation of Distinct NF-κB Factors via Separate Signaling Pathways* , 2003, The Journal of Biological Chemistry.

[42]  S. Curley,et al.  Role of Rel/NF‐κB transcription factors in apoptosis of human hepatocellular carcinoma cells , 2002, Cancer.

[43]  M. Magnuson,et al.  DNA excision in liver by an albumin‐Cre transgene occurs progressively with age , 2000, Genesis.

[44]  J. Olynyk,et al.  Oval cell numbers in human chronic liver diseases are directly related to disease severity. , 1999, The American journal of pathology.

[45]  P. Scheuer.  Pathologic Features and Evolution of Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis , 1998 .

[46]  J. Hoofnagle,et al.  Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.

[47]  R. Wiesner,et al.  Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis , 1981, Hepatology.